Safety of Biologics Therapy Monoclonal Antibodies, Cytokines, Fusion Proteins, Hormones, Enzymes, Coagulation Proteins, Vaccines, Botulinum Toxins /

This long overdue title provides a comprehensive, up-to-date, state-of-the art review of approved biologic therapies, with coverage of mechanisms of action, Indications for therapy, immunogenicity and a detailed examination of adverse effects and safety of the many and diverse therapeutic agents pre...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριος συγγραφέας: Baldo, Brian A. (Συγγραφέας)
Συγγραφή απο Οργανισμό/Αρχή: SpringerLink (Online service)
Μορφή: Ηλεκτρονική πηγή Ηλ. βιβλίο
Γλώσσα:English
Έκδοση: Cham : Springer International Publishing : Imprint: Springer, 2016.
Θέματα:
Διαθέσιμο Online:Full Text via HEAL-Link
LEADER 03236nam a22004695i 4500
001 978-3-319-30472-4
003 DE-He213
005 20171007071824.0
007 cr nn 008mamaa
008 160812s2016 gw | s |||| 0|eng d
020 |a 9783319304724  |9 978-3-319-30472-4 
024 7 |a 10.1007/978-3-319-30472-4  |2 doi 
040 |d GrThAP 
050 4 |a RC681-688.2 
072 7 |a MJD  |2 bicssc 
072 7 |a MED010000  |2 bisacsh 
082 0 4 |a 616.12  |2 23 
100 1 |a Baldo, Brian A.  |e author. 
245 1 0 |a Safety of Biologics Therapy  |h [electronic resource] :  |b Monoclonal Antibodies, Cytokines, Fusion Proteins, Hormones, Enzymes, Coagulation Proteins, Vaccines, Botulinum Toxins /  |c by Brian A. Baldo. 
264 1 |a Cham :  |b Springer International Publishing :  |b Imprint: Springer,  |c 2016. 
300 |a XXI, 610 p. 106 illus., 89 illus. in color.  |b online resource. 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
347 |a text file  |b PDF  |2 rda 
520 |a This long overdue title provides a comprehensive, up-to-date, state-of-the art review of approved biologic therapies, with coverage of mechanisms of action, Indications for therapy, immunogenicity and a detailed examination of adverse effects and safety of the many and diverse therapeutic agents presented in a total of 13 chapters.  It is predicted that by 2016, biologics will make up half of the world's 20 top-selling drugs and by 2018, biologic medicine sales will account for almost half of the world's 100 biggest selling drugs. Recombinant proteins dominate the growing list of the more than 200 approved biotherapeutic agents with targeted antibodies, fusion proteins and receptors; cytokines; hormones; enzymes; proteins involved in blood-clotting, homeostasis and thrombosis; vaccines; botulinum neurotoxins; and, more recently, biosimilar preparations, comprising the majority of approved biologics. Written with clinicians, other health care professionals, and researchers in mind, Safety of Biologics Therapy examines, in a single volume, the full range of issues surrounding the safety of approved biologic therapies. A good understanding of the risks and safety issues of modern biologics therapy is increasingly being demanded of all those connected with their development, handling, prescribing, administration and subsequent patient management. In addition to being of great value to clinicians in all branches of medicine, and to nurses, pharmacists and researchers, this book will prove invaluable for students taking undergraduate and graduate courses in the above disciplines and in the biomedical sciences. 
650 0 |a Medicine. 
650 0 |a Cardiology. 
650 0 |a Endocrinology. 
650 0 |a Gastroenterology. 
650 0 |a Oncology. 
650 1 4 |a Medicine & Public Health. 
650 2 4 |a Cardiology. 
650 2 4 |a Endocrinology. 
650 2 4 |a Gastroenterology. 
650 2 4 |a Oncology. 
710 2 |a SpringerLink (Online service) 
773 0 |t Springer eBooks 
776 0 8 |i Printed edition:  |z 9783319304700 
856 4 0 |u http://dx.doi.org/10.1007/978-3-319-30472-4  |z Full Text via HEAL-Link 
912 |a ZDB-2-SME 
950 |a Medicine (Springer-11650)